Author Archives: Denis Serban

Avacta to Launch SARS-CoV-2 ELISA laboratory test

Avacta is planning to launch an ELISA laboratory test for the SARS-CoV-2 spike protein to support global research efforts into the coronavirus that causes COVID-19. Enzyme linked immunosorbent assays (ELISAs) are very common research tools used to detect and quantify a target of interest in a range of… Read More

#News

CSL to supply two vaccine candidates for Australia

CSL has signed an agreement with the Australian government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451). In a separate agreement with AstraZeneca it will also manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful. Read More

#News

#Narrated podcasts

From Genotype to Phenotype: Leveraging functional genomics in oncology

Drug discovery is increasingly informed by genomics, which can significantly boost the chances of a novel therapy successfully navigating the lengthy journey from bench to bedside. But despite the rapid proliferation of genomic information, we still have a limited understanding of how specific genes and genetic variations drive tumour growth… Read More

#Podcasts

#Narrated podcasts

Flow Cytometry – The advanced systems overcoming drug discovery pain points

Flow cytometry is an invaluable technique for the characterisation of highly heterogeneous cell populations. Thanks to improvements in throughput, automation and multichannel detection capabilities, recent years have seen its use expand across a wide range of drug discovery applications. In this article, we look at novel developments in flow cytometer… Read More

#Podcasts

#Narrated podcasts

Cell Therapy – Falling short of its potential?

Despite major investment in the field, few cell therapies have gained regulatory approval with limited commercial success. The success of therapeutic products is defined by three factors: safety, efficacy and scalability. Achieving these for cell therapy presents new challenges; overcoming transplant rejection (and GvHD in the case of immune cells),… Read More

#Podcasts